Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
9.34
-0.11 (-1.16%)
Nov 22, 2024, 4:00 PM EST - Market closed
Company Description
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 452 |
| CEO | Terrie Curran |
Contact Details
Address: 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 United States | |
| Phone | 877 742 8466 |
| Website | phathompharma.com |
Stock Details
| Ticker Symbol | PHAT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001783183 |
| CUSIP Number | 71722W107 |
| ISIN Number | US71722W1071 |
| Employer ID | 82-4151574 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Terrie J. Curran | President, Chief Executive Officer and Director |
| David A. Socks | Co-Founder and Director |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder and Chief Operating Officer |
| Molly Henderson CPA, MBA | Chief Financial and Business Officer |
| Dr. Aditya Kohli Ph.D. | Co-Founder |
| Paul Cocja | Chief People Officer |
| Tom Harris | Chief Development Sciences Officer |
| Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer |
| Martin J. Gilligan | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 5, 2024 | SCHEDULE 13G/A | Filing |
| Nov 5, 2024 | SCHEDULE 13G | Filing |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 22, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 19, 2024 | 8-K | Current Report |
| Aug 19, 2024 | 424B5 | Filing |